Potential and limitations of modern combined asthma therapy
Inhalation glucocorticosteroid (ICS) and long-acting ?2-adrenoagonist (LABA) combination currently is the basis of bronchial asthma (BA) treatment in adults with moderate and severe BA, in children with severe BA. The appearance of combination therapies with ICS and LABA components reflects the evolution of views on the asthma treatment. Studies have shown that the use of LABA such as salmeterol and formoterol not only prevent nocturnal asthma symptoms and asthma of physical effort, but also reduce the dose of ICS required achieving adequate control of asthma.

Keywords: long-acting beta2-adrenoagonists, inhalation glucocorticosteroids, bronchial asthma, combination therapy